Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment

Eli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country's large population. This inclusion follows the earlier reimbursement of rival Novo Nordisk's Ozempic. While national listing boosts availability, prices are typically negotiated lower.